Topic Issue
Reducing LDL Cholesterol to Prevent Atherosclerotic Cardiovascular Disease AUGUST 2018 ĦE VOL. 10 ĦE NO. 5
COPD with Comorbid Diabetes Mellitus MAY 2018 ĦE VOL. 10 ĦE NO. 4
The More I Know, The More I Know That I Don't Know APRIL 2018 ĦE VOL. 10 ĦE NO. 3
What's Next After Metformin? How to Choose the Second Anti-Diabetic Drug in a Primary Care Setting APRIL 2018 ĦE VOL. 10 ĦE NO. 3
Advancements in Obesity Medicine in the Past Decade APRIL 2018 ĦE VOL. 10 ĦE NO. 3
Screening and Management of Diabetic Nephropathy APRIL 2018 ĦE VOL. 10 ĦE NO. 3
Coronary Artery Disease Screening in Patients with Type 2 Diabetes APRIL 2018 ĦE VOL. 10 ĦE NO. 3
Metabolic Syndrome and Perspectives for Future Research: A Brief Review JANUARY 2018 ĦE VOL. 10 ĦE NO. 1
Latest Insights on the Treatment of Dyslipidemia NOVEMBER 2017 ĦE VOL. 9 ĦE NO. 7
Recent Advances in the Management of Type 2 Diabetes NOVEMBER 2017 ĦE VOL. 9 ĦE NO. 7
Clinical Benefits of the Potent Antioxidant Probucol NOVEMBER 2017 ĦE VOL. 9 ĦE NO. 7
Insulin Initiation in Patients with Type 2 Diabetes JULY 2017 ĦE VOL. 9 ĦE NO. 5
Comorbidities of Gout APRIL 2017 ĦE VOL. 9 ĦE NO. 3
SGLT2 Inhibitors: A New Class of Antidiabetic Drugs NOVEMBER 2016 ĦE VOL. 8 ĦE NO. 7
Oxidative Stress and Inflammation in Atherosclerosis NOVEMBER 2016 ĦE VOL. 8 ĦE NO. 7
SGLT2 Inhibitors: A New Class of Antidiabetic Drugs SEPTEMBER 2016 ĦE VOL. 8 ĦE NO. 6
Management of Obesity in Patients with Type 2 Diabetes SEPTEMBER 2016 ĦE VOL. 8 ĦE NO. 6
The Important Role of Diet in the Management of Hypercholesterolemia and Prevention of Coronary Heart Disease JULY 2016 ĦE VOL. 8 ĦE NO. 5
Gout: What is the Treatment Target and How to Achieve the Target? FEBRUARY 2016 ĦE VOL. 8 ĦE NO. 2
Pharmacogenomics: The Promises of Personalized Medicine JANUARY 2016 ĦE VOL. 8 ĦE NO. 1
The Impact of GLP-1 Receptor Agonists on Weight in Obese Patients with Type 2 Diabetes Mellitus DECEMBER 2015 ĦE VOL. 7 ĦE NO. 7
Role of Probucol in the Current Treatment of Atherosclerosis and Vascular Disease NOVEMBER 2015 ĦE VOL. 7 ĦE NO. 6
2015 Update in Diabetes, Endocrinology & Metabolism NOVEMBER 2015 ĦE VOL. 7 ĦE NO. 6
Probucol: Reappraisal of an Old Drug for Atherosclerosis MAY 2015 ĦE VOL. 7 ĦE NO. 3
Year of Endocrinology, Diabetes & Metabolism 2014 NOVEMBER 2014 ĦE VOL. 6 ĦE NO. 6
Update on the Use of Angiotensin Receptor Blockers in Hypertension: A Focus on Azilsartan Medoxomil JUNE 2014 ĦE VOL. 6 ĦE NO. 3
Update on Gout Management DECEMBER 2013 ĦE VOL. 5 ĦE NO. 7
Type 2 Diabetes and Comorbidities: The Management Challenges DECEMBER 2013 ĦE VOL. 5 ĦE NO. 7
Blood Pressure Variability: Is It Important and How Can We Assess It? DECEMBER 2013 ĦE VOL. 5 ĦE NO. 7
Glucocorticoid-Induced Osteoporosis - Who Should be Treated MAY 2013 ĦE VOL. 5 ĦE NO. 3
Heart Rate Reduction as a Goal in the Management of Cardiovascular Risk MARCH 2013 ĦE VOL. 5 ĦE NO. 2
Role of Bone Mineral Density in Fracture Risk Assessment MARCH 2013 ĦE VOL. 5 ĦE NO. 2
Update on Management of Gout and Hyperuricaemia JANUARY 2013 ĦE VOL. 5 ĦE NO. 1
New Directions in Management Type 2 Diabetes Mellitus DECEMBER 2012 ĦE VOL. 4 ĦE No. 7
The Role of Combination Therapy in the Management of Hypertension MAY 2012 ĦE VOL. 4 ĦE NO. 3
Update in Oral Antidiabetic Drugs in Type 2 Diabetes DECEMBER 2011 ĦE VOL. 3 ĦE NO. 7
Niacin for the Treatment of Dyslipidaemia and Atherosclerosis JULY 2011 ĦE VOL. 3 ĦE NO. 4
Atypical Femoral Fractures and Bisphosphonates: New Aspects MAY 2011 ĦE VOL. 3 ĦE NO. 3
New Treatment Modalities in Osteoporosis MARCH 2011 ĦE VOL. 3 ĦE NO. 2
Recent Advances in Therapeutics in Osteoporosis JANUARY 2011 ĦE VOL. 3 ĦE NO. 1
The Role of thiazolidinediones in the Management of Type 2 Diabetes DECEMBER 2010 ĦE VOL. 2 ĦE NO. 8
Increase in Bone Mineral Density During Testosterone Therapy in Chinese Hypogonadal Men MAY 2010 ĦE VOL. 2 ĦE NO. 3
Differential Diagnosis of Hypercalcaemia APRIL 2009 ĦE VOL. 1 ĦE NO. 2
This website is restricted for use by medical doctors only.
Disclaimer
| Terms of use | Privacy Statement
Copyright © 2006 The Society of Physicians of Hong Kong.